Trial reportDiabetes technology & therapeutics2016
Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 Diabetes.
Trial report in Diabetes technology & therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Advances in Insulin Infusion Set in the New Era of Automated Insulin Delivery: A Systematic Review.Journal of diabetes science and technology · 2023Pooled it
- Real-Time Detection of Infusion Site Failures in a Closed-Loop Artificial Pancreas.Journal of diabetes science and technology · 2018Trial
- Application of Zone Model Predictive Control Artificial Pancreas During Extended Use of Infusion Set and Sensor: A Randomized Crossover-Controlled Home-Use Trial.Diabetes care · 2017Trial
- Observational Study of the Impact of Infusion Set Replacement in Insulin Pump Users on Glycemic Management.Journal of diabetes science and technology · 2025Article
- A Glucose-Responsive Cannula for Automated and Electronics-Free Insulin Delivery.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Development of the Extended Infusion Set and Its Mechanism of Action.Journal of diabetes science and technology · 2024Article
- Impact of Infusion Set Materials and Designs on the Subcutaneous Response in People With Diabetes: A Rapid Review of the Literature.Journal of diabetes science and technology · 2023Review
- Insulin Delivery Hardware: Pumps and Pens.Diabetes technology & therapeutics · 2023Article
- Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial.Diabetes technology & therapeutics · 2022Article
- Machine Learning-Based Anomaly Detection Algorithms to Alert Patients Using Sensor Augmented Pump of Infusion Site Failures.Journal of diabetes science and technology · 2022Article
- Improving the Patient Experience With Longer Wear Infusion Sets Symposium Report.Journal of diabetes science and technology · 2022Article
- Insulin induces a progressive increase in the resistance of subcutaneous tissue to fluid flow: Implications for insulin pump therapy.Diabetes, obesity & metabolism · 2022Article
- Longevity of the novel ConvaTec infusion set with Lantern technology.Diabetes, obesity & metabolism · 2021Article
- Advancing continuous subcutaneous insulin infusion in vivo: New insights into tissue challenges.Journal of biomedical materials research. Part A · 2021Article
- Detection of Insulin Pump Malfunctioning to Improve Safety in Artificial Pancreas Using Unsupervised Algorithms.Journal of diabetes science and technology · 2019Article
- Preserving Skin Integrity with Chronic Device Use in Diabetes.Diabetes technology & therapeutics · 2018Article
- Detailed Analysis of Insulin Absorption Variability and the Tissue Response to Continuous Subcutaneous Insulin Infusion Catheter Implantation in Swine.Diabetes technology & therapeutics · 2017Article
- Insulin Infusion Sets and Continuous Glucose Monitoring Sensors: Where the Artificial Pancreas Meets the Patient.Diabetes technology & therapeutics · 2017Article
- Continuous Glucose Monitoring Enables the Detection of Losses in Infusion Set Actuation (LISAs).Sensors (Basel, Switzerland) · 2017Article
- Algorithms for a Single Hormone Closed-Loop Artificial Pancreas: Challenges Pertinent to Chemical Process Operations and Control.Processes (Basel, Switzerland) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundImproved insulin infusion set survival and faster insulin action are important issues for pump users and for the development of an artificial pancreas. The current recommendation is to change infusion sets every 3 days. Our objectives were to determine the effect of lipohypertrophy (LH) on infusion set survival and continuous glucose monitoring glucose levels. RESEARCH DESIGN AND
methodsIn this multicenter crossover trial, we recruited 20 subjects (age 28.1 ± 9.0 years) with type 1 diabetes (duration 17.5 ± 8.8 years) and an area of lipohypertrophied tissue >3 cm. Subjects alternated weekly wearing a Teflon infusion set in an area of either LH or non-LH for 4 weeks. Sets were changed after (a) failure or (b) surviving 7 days of use.
resultsThe least-squares mean duration of infusion set survival for sets that lasted <7 days in lipohypertrophied tissue was 4.31 days compared with 4.12 days in nonlipohypertrophied tissue (P = 0.71). The average duration of set survival for individual subjects ranged from 2.2 to 7.0 days. Infusion sets in lipohypertrophied tissue failed due to hyperglycemia in 35% of subjects compared with 23% in nonlipohypertrophied tissue (P = 0.22). Both lipohypertrophied and nonlipohypertrophied tissues displayed a general increase in mean daily glucose after the third day of infusion set wear, but daily mean glucose did not differ by tissue type (P > 0.38 on each day).
conclusionLH did not significantly affect infusion set survival or mean glucose. Achieving optimal infusion set performance requires research into factors affecting set survival. Additionally, the recommendation for duration of set change may need to be individualized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.